Enovis (ENOV): insider & executive buying
Enovis · Health Care · ref. ETF XLV · price $24.83
In short — 1 insider bought Enovis over ~6 months (4 buys, total $124k, latest Jun 11, 26). Public Form 4 data, informative (not a performance signal).
Are Enovis's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$24.83-18.8% over range
Aug 28, 25low $20.04 · high $33.32Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 5 analysts
Latest insider buys on Enovis
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| Jun 11, 26 | Engert Oliver | Chief Administrative Officer | 1,200 | $26k |
| Mar 6, 26 | Engert Oliver | Chief Administrative Officer | 1,750 | $42k |
| Mar 3, 26 | Engert Oliver | Chief Administrative Officer | 1,250 | $31k |
| Feb 27, 26 | Engert Oliver | Chief Administrative Officer | 1,000 | $26k |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Enovis's executives bought shares recently?
1 Enovis insider(s) bought $124k over ~6 months (latest Jun 11, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for ENOV?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Enovis? The JPI assistant answers using our backtest data.
Keep exploring Enovis